Keyword: GlaxoSmithKline

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Despite the FDA sending it back to the drawing board late last year, GSK's ViiV won over Canadian regulators with once-monthly HIV regimen Cabenuva.

Albert Bourla's 2019 compensation jumped 82% over 2018's, but promotion to Pfizer's top job wasn't the only factor that boosted his pay.

As COVID-19 spreads, pharma's forcing sales reps to stay at home, subbing digital tools and virtual meetings for face-to-face physician visits.

J&J CAR-T partner Legend aims for U.S. IPO. The FDA's not sure how many drugs and APIs come from China. Harbour teams with Mount Sinai on coronavirus.

For the second time in three weeks, the GlaxoSmithKline and Pfizer consumer joint venture has named a plant it will divest to raise cash for its JV.

Data showed a combo of ViiV's cabotegravir and J&J's rilpivirine given very two months was similarly effective to once-monthly Cabenuva.

Multinational drugmakers are restricting travel and limiting gatherings—and requiring vendors to do the same—as COVID-19 breaks out worldwide.

The major contribution to her pay growth comes from vesting of long-term awards, which totaled £5.08 million.

GSK tried to sell its cephalosporin brands two years ago but failed. This time, a potential divestiture could fit into CEO Walmsley’s overhaul plan.